JOBS
:::All positions have been filled:::
THE PROJECT
In 2035, cancer will have become the leading cause of death in the EU. Therapy resistance is a key contributor to high recurrence rates, morbidity, and mortality. Esophageal adenocarcinoma (EAC) is the most common type of esophageal cancer in the Western world, and a prime example of a cancer that is highly resistant to therapy. Despite recent developments of treatment strategies, long-term survival remains low. Prominent factors that contribute to the poor outcome of EAC are a high degree of acquired resistance, and heterogeneous responses to therapies. Additionally, to improve EAC treatment outcome, molecular and cellular mechanisms of resistance need to be further understood.
The PRESSURE consortium brings together expert groups from the Netherlands, Germany, Italy, Sweden, Czech Republic, France, and Denmark, to address key challenges that preclude the effective treatment of EAC: A consensus treatment in the EU based on real-world efficacy data is lacking. Establishing such data and unified treatment will avoid the detrimental effects of some therapies. Likewise, the current fragmentation of expertise and tools across Europe prevents an effective development of new approaches. PRESSURE members have independently amassed a wealth of samples, disease models, clinical data, scientific know-how, and cutting-edge technologies. In the consortium, these elements will be joined to develop novel and optimized treatment strategies and diagnostics. We will employ 10 researchers to address these scientific challenges by performing research in academic and industrial groups, and by doing so receive exhaustive training across relevant disciplines and sectors.
POSITIONS OFFERED
Nine PhD position are currently offered, of which one will start November 2023, and eight on February 2024. A tenth position starting on November 2024 will be posted at a later moment. The offered individual research projects are biomedical, epidemiological, and biophysical in nature. Below are listed descriptions of the available positions, also stating candidate requirements, and planned secondments to other consortium members.
Note that the MSCA-ITN mobility clause applies; the applicant may not have spent 12 months or more in the past 3 years in the country where the position is offered. Candidates may not already hold a doctoral degree. Candidate must be eligible to work according to your host country’s regulations (for instance visa requirements), and to work in other European countries for secondments and meetings.
SELECTION PROCESS
Please submit your application until November 1st. Note that your application may be forwarded to other Beneficiaries in the consortium.
Please include the following documents:
- Letter of motivation/research statement (1-2 pages). This should include a description of past work, but also a vision on how you see yourself fit in the consortium and the position you are applying for.
- Curriculum vitae (CV)
- Contact information for 2-3 references
